SphingoTec develops and markets innovative IVD solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice.
Our innovative biomarkers address diagnostically underserved acute and critical care conditions such as acute kidney injury, sepsis, and acute heart failure. The solutions we have created combine scientific discoveries with medical research and robust technologies to support clinicians in improving patient care. We work with internationally leading academic and non-academic medical centers as well as global IVD and pharma companies to bring these innovations closer to the patients.